Lung Cancer and the role of radiotherapy Flashcards

(32 cards)

1
Q

What is the pimary risk factor in lung cancer?

A

Smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Name the common symptoms of lung cancer

A

Persistent cough - 3/4 weeks
SOB
A cough that gets worse
Repeat chest infections
Loss of appetite
Hemoptysis (blood in sputum)
Weight loss
Dyspnoea
Chest pain
Blood clots
Horseness
Finger clubbing
Unexplained fatigue to lack of energy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

How is lung cancer diagnosed?

A

Bronchoscopy
CT-guided biopsy
EBUS
Surgical biopsy
PET-CT
Molecular profiling - EGFR, ALK, ROS1, PDL1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Name the 2 subtypes of lung cancer

A

NSCLC - non-small cell lung cancer
SCLC- small cell lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Describe NSCLC

A

Non small cell lung cncer (85-90%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Describe SCLC

A

Small cell lung cancer
(10-15%)
aggressive, rapid spread
often treated with chemo/radiotherapy not surgery
usually caused by smoking

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Describe the limited stage

A

Can be encompassed by radiotherapy
Optimal treatment is 4 cycles of chemotherapy combined with radiotherapy
Median overall survival is 2 years, 5 years survival 33%

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Describe the extensive stage

A

More common presentation
Chemotherapy (carboplatin + etoposide) - approx 10 months due to resistance it often comes back
Chemo-immunotherapy (addition of atezolizumab) approx 12 months
40% risk of brain metastases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the criteria for NSCLC surgery?

A

N0/N1 not T4
Good lung function, co-morbidities (smokers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Define neo-adjuvant

A

Refers to treatment given before the main treatment usually surgery to shrink the tumour or improve the outcome of the primary intervention

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Name common Neo-adjuvant therapies

A

Chemotherapy
Radiotherapy
Hormonal therapy
Targeted therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What is the purpose of Neo-adjuvant therapy?

A

Reduce the tumour size to make surgery easir or more effective
allow less invasive surgery
Kill micrometases (tiny undetectable cancer cells)
Assess tumour response to treatment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Define adjuvant

A

Given after the primary treatment (usually surgery) to eliminate any remaining cancer cells and reduce the risk of recurrence

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Name the common types of adjuvant therapy

A

Chemotherapy
Radiotherapy
Hormonal Therapy
Targeted therapy
Immunotherapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is the purpose of adjuvant therapy?

A

Destroy any microscopic disease left behind after surgery
Lower the chance of cancer coming back
Improve long-term survival outcomes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Describe adjuvant therapy given for the treatment of NSCLC

A

๐Ÿงช Adjuvant Chemotherapy (Cisplatin + Vinorelbine)
4โ€“5% survival improvement at 5 years

Given within 12 weeks post-surgery

Used if tumor >4 cm or lymph node involvement

Not all patients are fit enough to start or complete it

17
Q

Describe neo-adjuvant therapy given for the treatment of NSCLC

A

๐Ÿ’‰ Neo-Adjuvant Chemotherapy + Nivolumab (Immunotherapy)
3 cycles before surgery

Event-free survival: 32 months (vs 21 months with chemo alone)

Complete pathological response: 24% (vs 4%)

More patients became eligible for surgery

No increase in surgical complications

18
Q

Describe adjivant immunotherapy treatment option for NSCLC

A

For high PD-L1 expressing tumors

57% reduced relapse risk (42 vs 35 months disease-free survival)

19
Q

Describe adjuvant targeted therapy (Osimertinib)

A

For EGFR-positive NSCLC

Approved for adjuvant use since 2023

20
Q

Define SABR

A

SABR is a highly precise form of radiation therapy that delivers very high doses of radiation to a well-defined tumor in the body, typically over 1 to 5 treatment sessions.Uses image guidance and motion management to account for breathing and movement

Often used in early-stage lung cancer, liver metastases, adrenal tumors, and spinal lesions

21
Q

What are the advantages of SABR?

A

Non-invasive
Shorter-treatment course than conventional radiotherapy
Often used when surgery is not an option

22
Q

Define conventional therapy

A

Cancer treatment that uses high-energy X-rays or particles to kill or damage cancer cells over a series of low-dose treatments.
involves delivering small doses of radiation to the cancer site daily over several weeks (usually 20-35 lesions)
Lower dose per session, but spread over more sessions

Often used for larger tumors or those near sensitive organs

Less precision than SABR, so wider margins are treated to ensure full coverage

23
Q

What are the advantages of conventional therapy?

A

Well established and widely available
Effective for many cancer types
Can be combined with chemotherapy (chemo radiation)

24
Q

What are the indications for conventional radiotherapy?

A

Inoperable non-metastatic disease => not fit enough, extensive, lots of lymph node involvement
Invasion or more extensive nodal (N2) involvement

25
Define SCAT and give examples
Is systemic anti-cancer therapy Examples include: Cytotoxic chemotherapy Targeted therapy (TKIs) Immunotherapy (IO) Antibody-Drug Conjugates (ADCs)
26
When is SCAT indicated?
Neo-adjuvant Adjuvant palliative
27
Define oncogenic drivers
Key Characteristics: Rare mutations that drive cancer growth More common in: Younger patients Females Never-smokers or light smokers
28
How do we test oncogenic drivers?
Primarily test adenocarcinomas Next Generation Sequencing (NGS) allows simulataneous testing for multiple oncogenic drivers
29
How do we treat oncogenic drivers?
Often require targeted therapies
30
How are the side effects of immunotherapies managed?
managed with steroids low grade toxicity - oral prednisolone high grade toxicity - IV methylprednisolone
31
32